An observational study in Breast Cancer, sponsored by AstraZeneca. Completed at 3 sites in Vietnam. Open to female participants. Per ClinicalTrials.gov, last updated 2011-06-22.
Sponsored by AstraZeneca · Observational
The purpose of this study is to describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) and estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-up.
12,543 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 259 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
The target study population comprised of postmenopausal women with early breast cancer who were treated with anastrozole for at least one month and are willing to give written informed consent to participate.
Exclusion Criteria:
To describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes)
Time frame: every 3- 6 months (4 visit in one year)
Estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-up
Time frame: every 3- 6 months (4 visit in one year)
Identify predictors of non- adherence
Time frame: every 3- 6 months (4 visit in one year)
The proportion of DFS after 1 year follow-up
Time frame: every 3- 6 months (4 visit in one year)
Describe menopausal symptoms
Time frame: every 3- 6 months (4 visit in one year)
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca